Restless Legs Syndrome Clinical Trial
Official title:
Sensorimotor Gating Studies in Restless Legs Syndrome
Verified date | April 14, 2009 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will explore what occurs between sensory and motor systems in restless legs
syndrome (RLS). Patients with RLS have uncomfortable sensations in the legs, usually in the
evening or early part of the night. Most patients also have periodic involuntary leg
movements. The condition tends to worsen over time, resulting in severe discomfort and sleep
disturbances.
Healthy normal volunteers and patients with RLS between 18 and 80 years of age may be
eligible for this study. All candidates will be screened with a medical history, physical and
neurological evaluations, electroymogram (measure of muscle activity), overnight sleep study,
electrocardiogram (ECG, measurement of the electrical activity of the heart), and blood and
urine tests. They may also have brain or spine magnetic resonance imaging (MRI) or
computerized tomography (CT) scans and a chest X-ray. Participants must stop taking all
medications prohibited by the study for 2 days or more before the study starts and throughout
its duration.
Participants will undergo prepulse inhibition tests to assess nervous system function. The
participant sits comfortably in a quiet room. Several cables are attached to the face and
legs using a special cream that conducts electrical signals through the cables to recording
equipment. Nervous system activity is evaluated while the subject is at rest and after
sensory stimulation (stimulating the nerves in the legs and face with a very brief electrical
current of mild to moderate intensity). At times, the subject receives a short, mild sound
stimulation delivered through earphones. The testing session takes 4 to 6 hours.
Status | Completed |
Enrollment | 45 |
Est. completion date | April 14, 2009 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
- INCLUSION CRITERIA: Subjects who meet all of the following inclusion criteria at screening will be eligible to participate in the study: 1. Male or female subjects aged 18 to 80. 2. For patients only, diagnosed with primary RLS based on the presence of a characteristic clinical history and the IRLSSG diagnostic criteria. 3. Normal physical and neurological examination. 4. Subject is willing to adhere to protocol requirements as evidenced by written, informed consent. 5. No clinically significant abnormalities on clinical chemistry or hematology examination at the pre-study medical evaluation. 6. Negative pre-study urine drug screen. EXCLUSION CRITERIA: Subjects meeting any of the following exclusion criteria will not be enrolled or will be immediately excluded from the study, as appropriate: 1. History of any medical condition that can reasonably be expected to compromise scientific integrity of the study; 2. Patient unwilling or unable to stop their usual mediations for RLS; 3. Subjects unable or unwilling to discontinue a prohibited concomitant medication 4. Subjects unwilling to sign an informed consent or to comply with protocol requirements. 5. Subjects with clinical and/or biological evidence of secondary RLS (e.g. renal failure (end-stage renal disease), iron deficient, anaemia or pregnancy at baseline). |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Neurological Disorders and Stroke (NINDS) |
United States,
Ondo W, Jankovic J. Restless legs syndrome: clinicoetiologic correlates. Neurology. 1996 Dec;47(6):1435-41. — View Citation
Silber MH. Restless legs syndrome. Mayo Clin Proc. 1997 Mar;72(3):261-4. Review. — View Citation
Walters AS. Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. Mov Disord. 1995 Sep;10(5):634-42. Review. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04786314 -
The Effect of Hot and Cold Water Application on Pregnant Women With Restless Leg Syndrome
|
N/A | |
Completed |
NCT01455012 -
Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome
|
Phase 4 | |
Terminated |
NCT01192503 -
Safety and Efficacy of Rasagiline in Restless Legs Syndrome
|
Phase 2/Phase 3 | |
Completed |
NCT00530530 -
ASP8825 - Study in Patients With Restless Legs Syndrome
|
Phase 2 | |
Completed |
NCT00721279 -
Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome
|
N/A | |
Completed |
NCT00942253 -
Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS)
|
Phase 2 | |
Completed |
NCT00375284 -
A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS
|
Phase 4 | |
Completed |
NCT00479531 -
Sequential Compression Devices for Treatment of Restless Legs Syndrome
|
Phase 3 | |
Recruiting |
NCT05581576 -
Pitolisant in Refractory Restless Legs Syndrome
|
Phase 4 | |
Active, not recruiting |
NCT03218969 -
Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist
|
Phase 1/Phase 2 | |
Recruiting |
NCT04144790 -
Impact of Iron Supplementation Treatment on Brain Iron Concentrations
|
||
Completed |
NCT05787080 -
Massage, Oxidative and Antioxidant Enzymes in Hemodialysis Patients With Restless Legs Syndrome(RLS)
|
N/A | |
Not yet recruiting |
NCT05529095 -
Sublingual Apomorphine in Refractory Restless Legs Syndrome
|
Phase 4 | |
Recruiting |
NCT05044520 -
Clinical Features Associated With Restless Legs Syndrome.
|
||
Withdrawn |
NCT03849001 -
Impact of Acute Leg Cycling at Various Intensities on RLS Severity in Persons With MS
|
N/A | |
Completed |
NCT03076541 -
Cardiovascular Variability, Heart Rate Response, and Electromyogram Power Associated With Periodic Leg Movements.
|
N/A | |
Recruiting |
NCT04145674 -
A Proof of Concept, Phase 2, Double-blind, Randomized Trial With d-Methadone Product Versus Placebo
|
Phase 2 | |
Completed |
NCT02532608 -
Infra-slow Oscillations During Sleep
|
N/A | |
Completed |
NCT01528462 -
Sleep Disorders Managed and Assessed Rapidly in Transient Ischemic Attack (TIA) and In Early Stroke
|
||
Completed |
NCT00748098 -
Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance
|
Phase 3 |